View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDelta 9 Cannabis 과거 순이익 실적과거 기준 점검 0/6Delta 9 Cannabis 의 수입은 연평균 -51.6%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 37.1%의 비율로 증가했습니다. 매출은 연평균 20.1%의 비율로 증가해 왔습니다.핵심 정보-51.62%순이익 성장률-45.56%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률23.06%매출 성장률20.12%자기자본이익률n/a순이익률-27.74%최근 순이익 업데이트31 Mar 2024최근 과거 실적 업데이트Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 17Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.06 loss in 3Q 2022)Third quarter 2023 results: CA$0.03 loss per share (improved from CA$0.06 loss in 3Q 2022). Revenue: CA$18.4m (up 18% from 3Q 2022). Net loss: CA$5.48m (loss narrowed 26% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.공고 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023Reported Earnings • Aug 15Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.공고 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023모든 업데이트 보기Recent updates공고 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.분석 기사 • Jun 21It's Unlikely That Shareholders Will Increase Delta 9 Cannabis Inc.'s (TSE:DN) Compensation By Much This YearKey Insights Delta 9 Cannabis to hold its Annual General Meeting on 28th of June CEO John Arbuthnot's total...Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.분석 기사 • May 10It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It LooksDelta 9 Cannabis Inc. ( TSE:DN ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...공고 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.Recent Insider Transactions Derivative • Apr 19Co-Founder exercised options to buy CA$31k worth of stock.On the 18th of April, John Arbuthnot exercised options to buy 1m shares at a strike price of around CA$0.045, costing a total of CA$56k. This transaction amounted to 9.9% of their direct individual holding at the time of the trade. Since June 2023, John's direct individual holding has increased from 11.52m shares to 12.13m. Company insiders have collectively sold CA$98k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.분석 기사 • Mar 26Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full StoryDelta 9 Cannabis Inc. ( TSE:DN ) shareholders have had their patience rewarded with a 122% share price jump in the last...분석 기사 • Mar 26Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price BoostDelta 9 Cannabis Inc. ( TSE:DN ) shareholders have had their patience rewarded with a 122% share price jump in the last...New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (CA$4.49m market cap, or US$3.31m).Reported Earnings • Nov 17Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.06 loss in 3Q 2022)Third quarter 2023 results: CA$0.03 loss per share (improved from CA$0.06 loss in 3Q 2022). Revenue: CA$18.4m (up 18% from 3Q 2022). Net loss: CA$5.48m (loss narrowed 26% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.공고 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023분석 기사 • Sep 09Is Delta 9 Cannabis (TSE:DN) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Aug 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 42% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (CA$9.04m market cap, or US$6.66m). Minor Risk Significant insider selling over the past 3 months (CA$191k sold).Reported Earnings • Aug 15Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (CA$11.6m market cap, or US$8.74m). Minor Risks Shareholders have been diluted in the past year (42% increase in shares outstanding). Significant insider selling over the past 3 months (CA$221k sold).분석 기사 • Jul 28Delta 9 Cannabis Inc. (TSE:DN) Not Doing Enough For Some Investors As Its Shares Slump 27%Delta 9 Cannabis Inc. ( TSE:DN ) shareholders won't be pleased to see that the share price has had a very rough month...공고 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023Recent Insider Transactions • Jun 23Co-Founder recently sold CA$99k worth of stockOn the 19th of June, John Arbuthnot sold around 2m shares on-market at roughly CA$0.056 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by CA$286k.Reported Earnings • May 17First quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.037 loss in 1Q 2022)First quarter 2023 results: CA$0.02 loss per share (improved from CA$0.037 loss in 1Q 2022). Revenue: CA$16.9m (up 35% from 1Q 2022). Net loss: CA$2.99m (loss narrowed 28% from 1Q 2022). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.공고 • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023공고 • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023Recent Insider Transactions • Dec 21Co-Founder recently sold CA$52k worth of stockOn the 13th of December, John Arbuthnot sold around 611k shares on-market at roughly CA$0.085 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by CA$276k.공고 • Dec 20Delta 9 Cannabis Inc. Announces Changes to Board of DirectorsDelta 9 Cannabis Inc. announced that Mr. Stuart Starkey has joined the Company's board of directors effective December 19, 2022. Mr. Starkey's appointment follows the previously announced resignation of Joanne Duhoux-Defehr as a director of the Company. Over the past 15 years, Mr. Starkey has been an entrepreneur, para-athlete, and non-profit founder. As President of Two Small Men Canada, Mr. Starkey grew a national moving chain to achieve corporate and franchise revenues of $35 Million per year with over 400 employees. As Co-founder of Mighty Moving Mr. Starkey grew a cross-docking and logistics business to service dozens of large chain retailers, with offices across Alberta. He has since successfully exited both Two Small Men Canada and Mighty Moving. During his tenure as a successful entrepreneur, Mr. Starkey realized the importance of businesses giving back to his community. In 2018, Mr. Starkey founded the Community of Big Hearts, a social enterprise with the purpose of getting businesses and people more involved within their communities, by making volunteering simple and engaging. The appointment of Mr. Starkey as a director of the Company remains subject to the approval of the Toronto Stock Exchange.Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance.Price Target Changed • Nov 16Price target decreased to CA$0.80Down from CA$0.95, the current price target is provided by 1 analyst. New target price is 567% above last closing price of CA$0.12. Stock is down 69% over the past year. The company posted a net loss per share of CA$0.11 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Nov 12Delta 9 Cannabis Inc. Provides Earnings Guidance for the Quarter and Nine Months Ended September 30, 2022Delta 9 Cannabis Inc. provided earnings guidance for the quarter and nine months ended September 30, 2022. For the quarter, the company anticipates anticipates revenue to be between $15.5 million and $15.8 million compared with $15.2 million for the same period last year.For nine months, the company anticipates revenue to be between $45.5 million and $45.8 million, compared to $45.2 million for the same period last year.공고 • Nov 11Delta 9 Cannabis Inc. to Report Q3, 2022 Results on Nov 14, 2022Delta 9 Cannabis Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022공고 • Sep 08Delta 9 Cannabis Inc. (TSX:DN) acquired All or Substantially All Assets from 10552763 Canada Corp.Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire All or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million on August 15, 2022. The Purchase Agreement includes several customary conditions in favor of the Company, including due diligence and the approval of the TSX. The Transaction is expected to close on or around August 29, 2022. Delta 9 Cannabis Inc. (TSX:DN) acquired All or Substantially All Assets from 10552763 Canada Corp. on September 6, 2022.분석 기사 • Aug 19Does Delta 9 Cannabis (TSE:DN) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Price Target Changed • Aug 17Price target decreased to CA$0.80Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 332% above last closing price of CA$0.18. Stock is down 57% over the past year. The company posted a net loss per share of CA$0.11 last year.Reported Earnings • Aug 16Second quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.014 loss in 2Q 2021)Second quarter 2022 results: CA$0.04 loss per share (down from CA$0.014 loss in 2Q 2021). Revenue: CA$17.5m (up 4.4% from 2Q 2021). Net loss: CA$4.83m (loss widened 249% from 2Q 2021). Over the next year, revenue is forecast to grow 42%, compared to a 26% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.공고 • Aug 16Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million.Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million on August 15, 2022. The Purchase Agreement includes several customary conditions in favor of the Company, including due diligence and the approval of the TSX. The Transaction is expected to close on or around August 29, 2022.공고 • Jul 28+ 2 more updatesJoanne Duhoux-Defehr Resigns from Board of Directors of Delta 9 Cannabis IncDelta 9 Cannabis Inc. announced that Joanne Duhoux-Defehr has resigned from the board of directors of the Company effective July 27, 2022.공고 • Jun 17Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,909 Price\Range: CAD 0.22 Discount Per Security: CAD 0.0154공고 • Jun 11Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,909 Price\Range: CAD 0.22 Discount Per Security: CAD 0.0154Price Target Changed • May 17Price target decreased to CA$0.95Down from CA$1.04, the current price target is provided by 1 analyst. New target price is 252% above last closing price of CA$0.27. Stock is down 46% over the past year. The company posted a net loss per share of CA$0.11 last year.Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 88% growth forecast for the industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.공고 • May 14+ 1 more updateDelta 9 Cannabis Inc. Provides Revenue Guidance for the Three Months Period Ended March 31, 2022Delta 9 Cannabis Inc. provided revenue guidance for the three months period ended March 31, 2022. For the period, the company expects revenue to be between $12.4 million and $12.6 million compared with $13.2 million for the same period last year.공고 • May 02Delta 9 Cannabis Inc., Annual General Meeting, Jun 29, 2022Delta 9 Cannabis Inc., Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 01Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 136% growth forecast for the pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.공고 • Apr 01Delta 9 Cannabis Inc. announced that it has received CAD 9.6 million in funding from Sundial Growers Inc.Delta 9 Cannabis Inc. announced that it has entered into a security purchase agreement for the issuance of senior secured second-lien convertible debentures for subscription price of CAD 9,600,000 on March 31, 2022. The transaction included participation from Sundial Growers Inc. The debenture is convertible into common shares at a conversion price of $0.35 per common share, if the company completes an offering of equity securities in the six months from the closing of the offering at an issuance price that is equal to or less than $0.29 per common share, the conversion price will be adjusted downward to a share price that is equal to a 20.0% premium to the issuance price of such offering of equity securities provided that, until shareholder approval is obtained by the company, such price is not less than the 5-day volume weighted average trading price of the common shares as of the date of the conversion of the holder floor price. The notes issued at original discount of 4% $10,000,000 in principal amount. The debentures will bear interest rate of 10% per annum, payable monthly. The debentures will mature on March 30, 2025.공고 • Jan 13Delta 9 Cannabis Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Year Ending December 31, 2021Delta 9 Cannabis Inc. provided preliminary unaudited earnings guidance for the fourth quarter and year ending December 31, 2021. For the quarter, the company expects net revenues to be between $16.6 million and $17.4 million. For the year, the company anticipates net revenues to be between $61.8 million and $62.6 million, compared to $52.1 million for the same period in the prior year.분석 기사 • Jan 11Is Delta 9 Cannabis (TSE:DN) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 17Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.07 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$15.2m (up 16% from 3Q 2020). Net loss: CA$1.12m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Oct 29Independent Director recently sold CA$126k worth of stockOn the 21st of October, Joanne Duhoux-Defehr sold around 326k shares on-market at roughly CA$0.39 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$154k more than they bought in the last 12 months.분석 기사 • Sep 28Delta 9 Cannabis (TSE:DN) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Price Target Changed • Aug 24Price target increased to CA$1.13Up from CA$1.04, the current price target is provided by 1 analyst. New target price is 176% above last closing price of CA$0.41. Stock is down 27% over the past year.Reported Earnings • Aug 18Second quarter 2021 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$16.8m (up 29% from 2Q 2020). Net loss: CA$1.39m (loss widened 64% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.공고 • Aug 12Delta 9 Cannabis Inc. Announces Health Canada Approval for Perimeter Expansion and Vault AreaDelta 9 Cannabis Inc. announced that on August 6, 2021, the company received approval from Health Canada for two expansion approvals for its Winnipeg based cultivation, processing, and distribution facilities. The Expansion Approval allows for; (i) an expansion of the Company’s licensed perimeter at its Winnipeg based facilities, expanding the area currently under license from approximately 80,000 square feet to approximately 95,000 square feet, and (ii) the licensing of a new 7,500 square foot purpose-built storage and distribution area. The expanded licensed perimeter will allow the Company to improve control systems within its licensed perimeter, improve the operational flow of its operations, and to position the Company to better plan for future expansions of the Company’s licensed cannabis operations areas. The new purpose-built storage and distribution area will allow the Company to improve its product packaging, case-packing, and distribution efficiency to better allow it to cater to its provincial distribution markets across Canada. The Company anticipates that the new storage area will improve its value proposition in various provincial markets across the country.Price Target Changed • Aug 11Price target decreased to CA$1.04Down from CA$1.15, the current price target is provided by 1 analyst. New target price is 145% above last closing price of CA$0.42. Stock is down 35% over the past year.Recent Insider Transactions Derivative • Jul 07Co-Founder exercised options to buy CA$63k worth of stock.On the 5th of July, John Arbuthnot exercised options to buy 143k shares at a strike price of around CA$0.49, costing a total of CA$71k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since September 2020, John's direct individual holding has decreased from 16.99m shares to 16.81m. Company insiders have collectively bought CA$106k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • Jun 27Co-Founder recently bought CA$53k worth of stockOn the 23rd of June, John Arbuthnot bought around 118k shares on-market at roughly CA$0.45 per share. In the last 3 months, they made an even bigger purchase worth CA$75k. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$125k.Recent Insider Transactions • Jun 26Co-Founder recently bought CA$53k worth of stockOn the 23rd of June, John Arbuthnot bought around 118k shares on-market at roughly CA$0.45 per share. In the last 3 months, they made an even bigger purchase worth CA$75k. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$125k.공고 • Jun 24Delta 9 Cannabis Inc. Provides Revenue Guidance for the Three-Month and Six-Month Period Ending June 30, 2021Delta 9 Cannabis Inc. provided revenue guidance for the three-month and six-month period ending June 30, 2021. For the three months, the company anticipates revenue to be between $15.5 million and $17.25 million. For the six months, the company anticipates revenue to be between $28.75 million and $30.5 million.Recent Insider Transactions • May 29Co-Founder recently sold CA$138k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly CA$0.51 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by CA$178k.Major Estimate Revision • May 25Consensus revenue estimates fall to CA$66.3mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$74.5m to CA$66.3m. Forecast losses increased from -CA$0.01 to -CA$0.06 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 120% next year. Consensus price target down from CA$1.15 to CA$1.12. Share price was steady at CA$0.51 over the past week.Recent Insider Transactions • May 22Co-Founder recently sold CA$115k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by CA$310k.Reported Earnings • May 19First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.공고 • May 07Delta 9 Cannabis Inc. Provides Revenue Guidance for the First Quarter Ending March 31, 2021Delta 9 Cannabis Inc. provided revenue guidance for the first quarter ending March 31, 2021. For the quarter, the company anticipates revenue to be between $12.90 million and $13.25 million.분석 기사 • Apr 08Delta 9 Cannabis (TSE:DN) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Apr 03Full year 2020 earnings released: CA$0.07 loss per share (vs CA$0.16 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 147% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.공고 • Mar 03Delta 9 Cannabis Inc. Provides Update on Strategic Cooperation Agreement with F1NE Cannabis Cultivation LTDDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Ontario based Micro Cultivation partner, F1NE Cannabis Cultivation LTD. (F1). As one of Delta 9’s Micro Cultivation partners, F1 entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the F1 brand and other services supporting the acquisition of the Health Canada license. On February 19, 2021, F1 confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are based on retrofitted 40-foot shipping containers. The turn key smart growing platforms are developed using precision hardware and software grow applications for the indoor cannabis cultivation marketplace. Delta 9 offers vertical growing units, integrated grow racks, and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and automated fertigation and watering systems. F1’s facility has been designed using this turn key and Grow Pod system. Once cultivation is harvested, Delta 9 plans to purchase the premium quality cannabis products from F1 for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Delta 9 has now successfully licensed over 100 Grow Pods in third party facilities across Canada.공고 • Feb 27Delta 9 Cannabis Inc. Launches Province Wide Delivery in Saskatchewan and Reserve Online in AlbertaDELTA 9 CANNABIS INC. announced that it has introduced new services to meet consumer demand for online ordering in all retail markets it serves. Delta 9 already has a robust online service in the Manitoba market and it has now launched a province wide delivery service in Saskatchewan and same-day home delivery service program to the Lloydminster, Saskatchewan marketplace. Delta 9 has also launched an online order service allowing customers to reserve products from Delta 9 stores in Calgary and Grande Prairie and have them ready for pick up within one hour. The Company to provide the next phase of convenience for customers and further enhance safety during the COVID -19 pandemic by minimizing contact time between customers and staff in its Alberta retail stores. With the click of a mouse, customers can browse through a complete inventory of cannabis products and reserve any products for pick up in the Delta 9 stores in Calgary and Grande Prairie and have it ready in one hour. The Company is also pleased to provide mail order delivery throughout the province of Saskatchewan as well as same day delivery in Lloydminster. Delta 9's online platform features allow an order to be ready in one hour or less along with same day local delivery services for the residents of Lloydminster, Saskatchewan. Customers will receive direct email order updates from their chosen store and can visit the Delta 9 website.공고 • Feb 11Delta 9 Cannabis Inc. to Report Q4, 2020 Results on Mar 30, 2021Delta 9 Cannabis Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 30, 2021공고 • Feb 05Delta 9 Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC announce that it has completed its final services milestone under an agreement with Alberta based Micro Cultivation partner, Dry Island LTD. (“Dry Island”). Dry Island is an arm’s length third party in which the Company has no ownership control or interest. On January 29, 2021, Dry Island confirmed it had reached its final milestone under the Strategic Cooperation Agreement (“SCA”) and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). As one of Delta 9’s Micro Cultivation partners, Dry Island entered into a Strategic Cooperation Agreement with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the Dry Island brand and other services supporting the acquisition of the Health Canada license.Dry Island has developed a micro cultivation facility on an 1/2-acre parcel of land, in Stettler, Alberta, that is half way between Calgary and Edmonton. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by Delta 9. Dry Island’s initial plan is to focus on growing two strains of 20+ THC before it expands its product offering. Dry Island owns two additional half acre adjacent lots to the property which are slated for future expansion. The well-rounded Dry Island team has a strong entrepreneurial background, with experience in construction and agriculture. The Dry Island team is committed and passionate about growing premium craft cannabis and looks forward to building a leading craft cannabis company in Alberta.Is New 90 Day High Low • Jan 28New 90-day low: CA$0.49The company is down 14% from its price of CA$0.57 on 29 October 2020. The Canadian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 79% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$3.34 per share.Recent Insider Transactions • Jan 22Independent Director recently sold CA$75k worth of stockOn the 13th of January, Hugh Aird sold around 150k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$679k more than they bought in the last 12 months.Recent Insider Transactions • Jan 17Independent Director recently sold CA$75k worth of stockOn the 13th of January, Hugh Aird sold around 150k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$679k more than they bought in the last 12 months.Recent Insider Transactions • Dec 25Co-Founder recently bought CA$98k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly CA$0.55 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$303k.공고 • Dec 24Delta 9 Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Manitoba based Micro Cultivation partner, Alicanto Gardens Ltd. (“Alicanto”). Alicanto is an arm’s length third party in which the company has no ownership control or interest. On December 18, 2020, Alicanto confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). As one of Delta 9’s Micro Cultivation partners, Alicanto entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the Alicanto brand and other services supporting the acquisition of the Health Canada license. The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are based on retrofitted 40-foot shipping containers. Alicanto’s production facility has been designed and built using this turnkey and state of the art Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Alicanto for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Delta 9 has now successfully licensed over 100 Grow Pods in third party facilities across Canada. Alicanto has developed a state-of-the-art micro cultivation facility on an 80-acre parcel of land, about ten minutes from Morris and an hour south of Winnipeg. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by Delta 9. Alicanto’s initial plan is to focus on growing a single strain of high THC before it expands its product offering. The well-rounded Alicanto team has a strong entrepreneurial background, with extensive experience in building a $50 million distribution business from the ground up over the last decade. The Alicanto team is committed and passionate about growing premium craft cannabis and looks forward to building a leading craft cannabis company in Manitoba.분석 기사 • Dec 24John Arbuthnot Is The Co-Founder of Delta 9 Cannabis Inc. (TSE:DN) And They Just Picked Up 1.0% More SharesWhilst it may not be a huge deal, we thought it was good to see that the Delta 9 Cannabis Inc. ( TSE:DN ) Co-Founder...Is New 90 Day High Low • Dec 24New 90-day low: CA$0.52The company is down 7.0% from its price of CA$0.56 on 24 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 67% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$3.51 per share.공고 • Dec 23Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 5.000001 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 5.000001 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,910 Price\Range: CAD 0.55 Discount Per Security: CAD 0.0385공고 • Dec 16Delta 9 Partners with Emterra Environmental to Create Sustainable Recycling and Landfill Diversion Program for Canadian Cannabis IndustryDELTA 9 CANNABIS INC. has partnered with Emterra Environmental, and a number of leading Canadian cannabis producers, to create a sustainable recycling program for cannabis packaging and disposable vape pens and a landfill diversion program for vape cartridges, that will help the Canadian cannabis industry transition to a circular economy. The new program will have two components. The first provides customers with a convenient option for the recycling of cannabis packaging similar to the well-known Blue Box Program. The second focuses on landfill diversion and uses the best technology currently available for the recycling of disposable vape cartridges and vape pens. The program will accept cannabis packaging, disposable vape pens and vape cartridges from every Licensed Producer, regardless of brand.공고 • Dec 12Delta 9 Cannabis Inc. Completes Final Services Milestone Under an Agreement with Prairie Craft CanopyDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Prairie Craft Canopy. PCC is an arm's length third party in which the Company has no ownership control or interest. As one of Delta 9's Micro Cultivation partners, PCC entered into a Strategic Cooperation Agreement ("SCA") with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the PCC brand and other services supporting the acquisition of the Health Canada license. On December 4, 2020, PCC confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the "Health Canada License"). PCC has developed a micro cultivation facility on a 10-acre parcel of land. The facility is in the RM of Edenwold No.158 just minutes from Regina, Saskatchewan. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by PCC. The facility includes some of the latest technology surrounding climate control and grow room automation. PCC plans to incorporate more innovative sustainability in future phases of expansion. PCC expects this facility to be the first step in a more significant growth strategy, as it makes plans for a second micro cultivation license and that will include another twelve-grow pod production capability in the near term. The well-rounded PCC Team has a strong entrepreneurial background, with an executive team that has many years experience in growing start-up companies. The PCC Team is committed and passionate about growing premium craft cannabis and looks forward to building a craft cannabis company in Saskatchewan. PCC expects to be in production by January, 2021 with plans to grow a unique strain of premium craft cannabis that consumers are looking for.공고 • Nov 26Delta 9 Cannabis Inc. Develops Proprietary Decontamination Technology to Help Fight COVID-19 PandemicDelta 9 Cannabis Inc. announced that it has developed and validated new proprietary decontamination equipment, branded the “Decontamination Pod” (or “D-Pod”), which can be used to decontaminate medical supplies, personal protective equipment (“PPE”), and other equipment. Canadian and US patent applications have been filed on behalf of the Company for the D-Pod, which is a standard shipping container retrofitted to include heating and ultraviolet light technologies. When PPE or other materials are placed inside the treatment area of the D-Pod, the combination of heat and UVC is sufficient to kill the COVID-19 virus. The Company, through a newly incorporated and partially owned subsidiary, Blue Horseshoe Manufacturing Inc., plans to manufacture and distribute the new technology across North America, providing a new tool for governments, health care facilities, long-term care facilities, businesses, and First Nations in their fight against COVID-19. The Company will leverage the success of its cannabis grow pod division which has produced and installed over 500 pods for in-house and third-party facilities since 2017 and use its existing cannabis grow pod manufacturing facilities in Winnipeg to manufacture the first D-Pods. Management believes that the Company will quickly be able to ramp up production capacity to 16 to 20 D-Pods per month, while working with other Canadian manufacturers to compliment its internal capacity. The D-Pods are expected to sell for approximately $250,000 per unit. The Company has already received inquiries from groups interested in deploying the technology and expects to begin taking orders in the coming week. The technology used in the D-Pods was originally developed in partnership between Delta 9, RSR Project Management Ltd., Northern Green Homes Inc., and Connco Electric and the finished D-Pod was tested and validated by an independent and accredited third party lab, BioScision Pharma Inc., which confirmed that the technology should be effective in decontaminating materials which may be contaminated with the COVID-19 virus. The D-Pod is the first innovation of Delta 9’s grow pod business unit which can be used as a tool in the fight against COVID-19. The Company is now developing additional technologies which can decontaminate equipment at low temperatures and modular storage and transport units which can be used to store and distribute vaccines while maintaining quality and stability.공고 • Nov 25Delta 9 Launches Click & Collect and Same Day Delivery Service in Thompson & Brandon, ManitobaDELTA 9 CANNABIS INC. announced that it has expanded its click-and-collect and same-day home delivery service program to the Thompson and Brandon, Manitoba markets. As a result, Delta 9 becomes the only retail store chain offering the above services in Winnipeg, Brandon, and Thompson, Manitoba. The Company is pleased to provide the next phase of convenience for customers and further enhance safety during the COVID-19 pandemic by minimizing contact time between customers and staff. With the click of a mouse, customers can browse and sort through a complete inventory of cannabis products by store and reserve any products from whichever retail location that is most convenient. Delta 9’s online platform features allow an order to be ready in two hours or less along with delivery services for all Manitobans. Customers will receive direct email and text order updates from their chosen store and can visit the Delta 9 website to seamlessly place an order. Customer service operators are available by phone or online chat.공고 • Nov 20Delta 9 Cannabis Inc. Completes Final Services Milestone Under an Agreement with Ahahswinis Green Investments LtdDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Ahahswinis Green Investments Ltd. ('Ahahswinis') which is 100% owned by Hupacasath First Nation. Ahahswinis is an arms length third party in which Delta 9 has no ownership control or interest. As one of Delta 9’s micro cultivation partners, Ahahswinis entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On November 13, 2020, Ahahswinis confirmed it has reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Ahahswinis’s facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Ahahswinis for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. The Hupacasath First Nation has owned and occupied their traditional territory in Central Vancouver Island for thousands of years. Their goal is to enhance the quality of life for their people by providing jobs and economic development opportunities so families can support themselves. They have invested $1.9 million in the 4,560 square foot micro cultivation operation with 12 Delta 9 Grow Pods, located outside of Port Alberni Vancouver Island, British Columbia.Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.공고 • Oct 30Delta 9 Cannabis Inc. to Report Q3, 2020 Results on Nov 12, 2020Delta 9 Cannabis Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 12, 2020공고 • Oct 27Delta 9 Cannabis Inc. Enters into Strategic Cooperation Agreement with Paradise Cannabis LtdDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, Paradise Cannabis LTD. Paradise is an arm’s length third party in which the Company has no ownership control or interest. As one of Delta 9’s Micro Cultivation partners, Paradise entered into a Strategic Cooperation Agreement with the company whereby Delta 9 provides services relating to the cannabis production facility design, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing and other services supporting the acquisition of the Health Canada license.매출 및 비용 세부 내역Delta 9 Cannabis가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSX:DN 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2471-2028031 Dec 2371-1828030 Sep 2371-2230030 Jun 2368-2431031 Mar 2368-2632031 Dec 2263-2731030 Sep 2263-2129030 Jun 2262-1427031 Mar 2262-1126031 Dec 2162-1125030 Sep 2159-824030 Jun 2157-1222031 Mar 2154-1322031 Dec 2052-621030 Sep 2048-818030 Jun 2042-418031 Mar 2038-317031 Dec 19321117030 Sep 19261219030 Jun 19211119031 Mar 19131017031 Dec 188-814030 Sep 183-1210030 Jun 182-117031 Mar 181-95031 Dec 171-83030 Sep 171-22030 Jun 171-22031 Mar 171-12031 Dec 160-12031 Dec 151-110양질의 수익: DN 은(는) 현재 수익성이 없습니다.이익 마진 증가: DN는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: DN은 수익성이 없으며 지난 5년 동안 손실이 연평균 51.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 DN의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: DN은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(225.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: DN의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/25 18:40종가2024/07/15 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Delta 9 Cannabis Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kimberly Thompson-HedlinCanaccord GenuitySiddharth RajeevFundamental Research Corp.Venkata VelagapudiResearch Capital Corporation
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 17Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.06 loss in 3Q 2022)Third quarter 2023 results: CA$0.03 loss per share (improved from CA$0.06 loss in 3Q 2022). Revenue: CA$18.4m (up 18% from 3Q 2022). Net loss: CA$5.48m (loss narrowed 26% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
공고 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
Reported Earnings • Aug 15Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
공고 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
공고 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.
분석 기사 • Jun 21It's Unlikely That Shareholders Will Increase Delta 9 Cannabis Inc.'s (TSE:DN) Compensation By Much This YearKey Insights Delta 9 Cannabis to hold its Annual General Meeting on 28th of June CEO John Arbuthnot's total...
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.
분석 기사 • May 10It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It LooksDelta 9 Cannabis Inc. ( TSE:DN ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...
공고 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.
Recent Insider Transactions Derivative • Apr 19Co-Founder exercised options to buy CA$31k worth of stock.On the 18th of April, John Arbuthnot exercised options to buy 1m shares at a strike price of around CA$0.045, costing a total of CA$56k. This transaction amounted to 9.9% of their direct individual holding at the time of the trade. Since June 2023, John's direct individual holding has increased from 11.52m shares to 12.13m. Company insiders have collectively sold CA$98k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
분석 기사 • Mar 26Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full StoryDelta 9 Cannabis Inc. ( TSE:DN ) shareholders have had their patience rewarded with a 122% share price jump in the last...
분석 기사 • Mar 26Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price BoostDelta 9 Cannabis Inc. ( TSE:DN ) shareholders have had their patience rewarded with a 122% share price jump in the last...
New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (CA$4.49m market cap, or US$3.31m).
Reported Earnings • Nov 17Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.06 loss in 3Q 2022)Third quarter 2023 results: CA$0.03 loss per share (improved from CA$0.06 loss in 3Q 2022). Revenue: CA$18.4m (up 18% from 3Q 2022). Net loss: CA$5.48m (loss narrowed 26% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
공고 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
분석 기사 • Sep 09Is Delta 9 Cannabis (TSE:DN) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Aug 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 42% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (CA$9.04m market cap, or US$6.66m). Minor Risk Significant insider selling over the past 3 months (CA$191k sold).
Reported Earnings • Aug 15Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (CA$11.6m market cap, or US$8.74m). Minor Risks Shareholders have been diluted in the past year (42% increase in shares outstanding). Significant insider selling over the past 3 months (CA$221k sold).
분석 기사 • Jul 28Delta 9 Cannabis Inc. (TSE:DN) Not Doing Enough For Some Investors As Its Shares Slump 27%Delta 9 Cannabis Inc. ( TSE:DN ) shareholders won't be pleased to see that the share price has had a very rough month...
공고 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
Recent Insider Transactions • Jun 23Co-Founder recently sold CA$99k worth of stockOn the 19th of June, John Arbuthnot sold around 2m shares on-market at roughly CA$0.056 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by CA$286k.
Reported Earnings • May 17First quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.037 loss in 1Q 2022)First quarter 2023 results: CA$0.02 loss per share (improved from CA$0.037 loss in 1Q 2022). Revenue: CA$16.9m (up 35% from 1Q 2022). Net loss: CA$2.99m (loss narrowed 28% from 1Q 2022). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
공고 • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023
공고 • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023
Recent Insider Transactions • Dec 21Co-Founder recently sold CA$52k worth of stockOn the 13th of December, John Arbuthnot sold around 611k shares on-market at roughly CA$0.085 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by CA$276k.
공고 • Dec 20Delta 9 Cannabis Inc. Announces Changes to Board of DirectorsDelta 9 Cannabis Inc. announced that Mr. Stuart Starkey has joined the Company's board of directors effective December 19, 2022. Mr. Starkey's appointment follows the previously announced resignation of Joanne Duhoux-Defehr as a director of the Company. Over the past 15 years, Mr. Starkey has been an entrepreneur, para-athlete, and non-profit founder. As President of Two Small Men Canada, Mr. Starkey grew a national moving chain to achieve corporate and franchise revenues of $35 Million per year with over 400 employees. As Co-founder of Mighty Moving Mr. Starkey grew a cross-docking and logistics business to service dozens of large chain retailers, with offices across Alberta. He has since successfully exited both Two Small Men Canada and Mighty Moving. During his tenure as a successful entrepreneur, Mr. Starkey realized the importance of businesses giving back to his community. In 2018, Mr. Starkey founded the Community of Big Hearts, a social enterprise with the purpose of getting businesses and people more involved within their communities, by making volunteering simple and engaging. The appointment of Mr. Starkey as a director of the Company remains subject to the approval of the Toronto Stock Exchange.
Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance.
Price Target Changed • Nov 16Price target decreased to CA$0.80Down from CA$0.95, the current price target is provided by 1 analyst. New target price is 567% above last closing price of CA$0.12. Stock is down 69% over the past year. The company posted a net loss per share of CA$0.11 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Nov 12Delta 9 Cannabis Inc. Provides Earnings Guidance for the Quarter and Nine Months Ended September 30, 2022Delta 9 Cannabis Inc. provided earnings guidance for the quarter and nine months ended September 30, 2022. For the quarter, the company anticipates anticipates revenue to be between $15.5 million and $15.8 million compared with $15.2 million for the same period last year.For nine months, the company anticipates revenue to be between $45.5 million and $45.8 million, compared to $45.2 million for the same period last year.
공고 • Nov 11Delta 9 Cannabis Inc. to Report Q3, 2022 Results on Nov 14, 2022Delta 9 Cannabis Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022
공고 • Sep 08Delta 9 Cannabis Inc. (TSX:DN) acquired All or Substantially All Assets from 10552763 Canada Corp.Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire All or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million on August 15, 2022. The Purchase Agreement includes several customary conditions in favor of the Company, including due diligence and the approval of the TSX. The Transaction is expected to close on or around August 29, 2022. Delta 9 Cannabis Inc. (TSX:DN) acquired All or Substantially All Assets from 10552763 Canada Corp. on September 6, 2022.
분석 기사 • Aug 19Does Delta 9 Cannabis (TSE:DN) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Price Target Changed • Aug 17Price target decreased to CA$0.80Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 332% above last closing price of CA$0.18. Stock is down 57% over the past year. The company posted a net loss per share of CA$0.11 last year.
Reported Earnings • Aug 16Second quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.014 loss in 2Q 2021)Second quarter 2022 results: CA$0.04 loss per share (down from CA$0.014 loss in 2Q 2021). Revenue: CA$17.5m (up 4.4% from 2Q 2021). Net loss: CA$4.83m (loss widened 249% from 2Q 2021). Over the next year, revenue is forecast to grow 42%, compared to a 26% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
공고 • Aug 16Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million.Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million on August 15, 2022. The Purchase Agreement includes several customary conditions in favor of the Company, including due diligence and the approval of the TSX. The Transaction is expected to close on or around August 29, 2022.
공고 • Jul 28+ 2 more updatesJoanne Duhoux-Defehr Resigns from Board of Directors of Delta 9 Cannabis IncDelta 9 Cannabis Inc. announced that Joanne Duhoux-Defehr has resigned from the board of directors of the Company effective July 27, 2022.
공고 • Jun 17Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,909 Price\Range: CAD 0.22 Discount Per Security: CAD 0.0154
공고 • Jun 11Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,909 Price\Range: CAD 0.22 Discount Per Security: CAD 0.0154
Price Target Changed • May 17Price target decreased to CA$0.95Down from CA$1.04, the current price target is provided by 1 analyst. New target price is 252% above last closing price of CA$0.27. Stock is down 46% over the past year. The company posted a net loss per share of CA$0.11 last year.
Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 88% growth forecast for the industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
공고 • May 14+ 1 more updateDelta 9 Cannabis Inc. Provides Revenue Guidance for the Three Months Period Ended March 31, 2022Delta 9 Cannabis Inc. provided revenue guidance for the three months period ended March 31, 2022. For the period, the company expects revenue to be between $12.4 million and $12.6 million compared with $13.2 million for the same period last year.
공고 • May 02Delta 9 Cannabis Inc., Annual General Meeting, Jun 29, 2022Delta 9 Cannabis Inc., Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 01Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 136% growth forecast for the pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
공고 • Apr 01Delta 9 Cannabis Inc. announced that it has received CAD 9.6 million in funding from Sundial Growers Inc.Delta 9 Cannabis Inc. announced that it has entered into a security purchase agreement for the issuance of senior secured second-lien convertible debentures for subscription price of CAD 9,600,000 on March 31, 2022. The transaction included participation from Sundial Growers Inc. The debenture is convertible into common shares at a conversion price of $0.35 per common share, if the company completes an offering of equity securities in the six months from the closing of the offering at an issuance price that is equal to or less than $0.29 per common share, the conversion price will be adjusted downward to a share price that is equal to a 20.0% premium to the issuance price of such offering of equity securities provided that, until shareholder approval is obtained by the company, such price is not less than the 5-day volume weighted average trading price of the common shares as of the date of the conversion of the holder floor price. The notes issued at original discount of 4% $10,000,000 in principal amount. The debentures will bear interest rate of 10% per annum, payable monthly. The debentures will mature on March 30, 2025.
공고 • Jan 13Delta 9 Cannabis Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Year Ending December 31, 2021Delta 9 Cannabis Inc. provided preliminary unaudited earnings guidance for the fourth quarter and year ending December 31, 2021. For the quarter, the company expects net revenues to be between $16.6 million and $17.4 million. For the year, the company anticipates net revenues to be between $61.8 million and $62.6 million, compared to $52.1 million for the same period in the prior year.
분석 기사 • Jan 11Is Delta 9 Cannabis (TSE:DN) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 17Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.07 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$15.2m (up 16% from 3Q 2020). Net loss: CA$1.12m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Oct 29Independent Director recently sold CA$126k worth of stockOn the 21st of October, Joanne Duhoux-Defehr sold around 326k shares on-market at roughly CA$0.39 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$154k more than they bought in the last 12 months.
분석 기사 • Sep 28Delta 9 Cannabis (TSE:DN) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Price Target Changed • Aug 24Price target increased to CA$1.13Up from CA$1.04, the current price target is provided by 1 analyst. New target price is 176% above last closing price of CA$0.41. Stock is down 27% over the past year.
Reported Earnings • Aug 18Second quarter 2021 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$16.8m (up 29% from 2Q 2020). Net loss: CA$1.39m (loss widened 64% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
공고 • Aug 12Delta 9 Cannabis Inc. Announces Health Canada Approval for Perimeter Expansion and Vault AreaDelta 9 Cannabis Inc. announced that on August 6, 2021, the company received approval from Health Canada for two expansion approvals for its Winnipeg based cultivation, processing, and distribution facilities. The Expansion Approval allows for; (i) an expansion of the Company’s licensed perimeter at its Winnipeg based facilities, expanding the area currently under license from approximately 80,000 square feet to approximately 95,000 square feet, and (ii) the licensing of a new 7,500 square foot purpose-built storage and distribution area. The expanded licensed perimeter will allow the Company to improve control systems within its licensed perimeter, improve the operational flow of its operations, and to position the Company to better plan for future expansions of the Company’s licensed cannabis operations areas. The new purpose-built storage and distribution area will allow the Company to improve its product packaging, case-packing, and distribution efficiency to better allow it to cater to its provincial distribution markets across Canada. The Company anticipates that the new storage area will improve its value proposition in various provincial markets across the country.
Price Target Changed • Aug 11Price target decreased to CA$1.04Down from CA$1.15, the current price target is provided by 1 analyst. New target price is 145% above last closing price of CA$0.42. Stock is down 35% over the past year.
Recent Insider Transactions Derivative • Jul 07Co-Founder exercised options to buy CA$63k worth of stock.On the 5th of July, John Arbuthnot exercised options to buy 143k shares at a strike price of around CA$0.49, costing a total of CA$71k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since September 2020, John's direct individual holding has decreased from 16.99m shares to 16.81m. Company insiders have collectively bought CA$106k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • Jun 27Co-Founder recently bought CA$53k worth of stockOn the 23rd of June, John Arbuthnot bought around 118k shares on-market at roughly CA$0.45 per share. In the last 3 months, they made an even bigger purchase worth CA$75k. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$125k.
Recent Insider Transactions • Jun 26Co-Founder recently bought CA$53k worth of stockOn the 23rd of June, John Arbuthnot bought around 118k shares on-market at roughly CA$0.45 per share. In the last 3 months, they made an even bigger purchase worth CA$75k. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$125k.
공고 • Jun 24Delta 9 Cannabis Inc. Provides Revenue Guidance for the Three-Month and Six-Month Period Ending June 30, 2021Delta 9 Cannabis Inc. provided revenue guidance for the three-month and six-month period ending June 30, 2021. For the three months, the company anticipates revenue to be between $15.5 million and $17.25 million. For the six months, the company anticipates revenue to be between $28.75 million and $30.5 million.
Recent Insider Transactions • May 29Co-Founder recently sold CA$138k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly CA$0.51 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by CA$178k.
Major Estimate Revision • May 25Consensus revenue estimates fall to CA$66.3mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$74.5m to CA$66.3m. Forecast losses increased from -CA$0.01 to -CA$0.06 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 120% next year. Consensus price target down from CA$1.15 to CA$1.12. Share price was steady at CA$0.51 over the past week.
Recent Insider Transactions • May 22Co-Founder recently sold CA$115k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by CA$310k.
Reported Earnings • May 19First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
공고 • May 07Delta 9 Cannabis Inc. Provides Revenue Guidance for the First Quarter Ending March 31, 2021Delta 9 Cannabis Inc. provided revenue guidance for the first quarter ending March 31, 2021. For the quarter, the company anticipates revenue to be between $12.90 million and $13.25 million.
분석 기사 • Apr 08Delta 9 Cannabis (TSE:DN) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Apr 03Full year 2020 earnings released: CA$0.07 loss per share (vs CA$0.16 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 147% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
공고 • Mar 03Delta 9 Cannabis Inc. Provides Update on Strategic Cooperation Agreement with F1NE Cannabis Cultivation LTDDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Ontario based Micro Cultivation partner, F1NE Cannabis Cultivation LTD. (F1). As one of Delta 9’s Micro Cultivation partners, F1 entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the F1 brand and other services supporting the acquisition of the Health Canada license. On February 19, 2021, F1 confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are based on retrofitted 40-foot shipping containers. The turn key smart growing platforms are developed using precision hardware and software grow applications for the indoor cannabis cultivation marketplace. Delta 9 offers vertical growing units, integrated grow racks, and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and automated fertigation and watering systems. F1’s facility has been designed using this turn key and Grow Pod system. Once cultivation is harvested, Delta 9 plans to purchase the premium quality cannabis products from F1 for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Delta 9 has now successfully licensed over 100 Grow Pods in third party facilities across Canada.
공고 • Feb 27Delta 9 Cannabis Inc. Launches Province Wide Delivery in Saskatchewan and Reserve Online in AlbertaDELTA 9 CANNABIS INC. announced that it has introduced new services to meet consumer demand for online ordering in all retail markets it serves. Delta 9 already has a robust online service in the Manitoba market and it has now launched a province wide delivery service in Saskatchewan and same-day home delivery service program to the Lloydminster, Saskatchewan marketplace. Delta 9 has also launched an online order service allowing customers to reserve products from Delta 9 stores in Calgary and Grande Prairie and have them ready for pick up within one hour. The Company to provide the next phase of convenience for customers and further enhance safety during the COVID -19 pandemic by minimizing contact time between customers and staff in its Alberta retail stores. With the click of a mouse, customers can browse through a complete inventory of cannabis products and reserve any products for pick up in the Delta 9 stores in Calgary and Grande Prairie and have it ready in one hour. The Company is also pleased to provide mail order delivery throughout the province of Saskatchewan as well as same day delivery in Lloydminster. Delta 9's online platform features allow an order to be ready in one hour or less along with same day local delivery services for the residents of Lloydminster, Saskatchewan. Customers will receive direct email order updates from their chosen store and can visit the Delta 9 website.
공고 • Feb 11Delta 9 Cannabis Inc. to Report Q4, 2020 Results on Mar 30, 2021Delta 9 Cannabis Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 30, 2021
공고 • Feb 05Delta 9 Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC announce that it has completed its final services milestone under an agreement with Alberta based Micro Cultivation partner, Dry Island LTD. (“Dry Island”). Dry Island is an arm’s length third party in which the Company has no ownership control or interest. On January 29, 2021, Dry Island confirmed it had reached its final milestone under the Strategic Cooperation Agreement (“SCA”) and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). As one of Delta 9’s Micro Cultivation partners, Dry Island entered into a Strategic Cooperation Agreement with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the Dry Island brand and other services supporting the acquisition of the Health Canada license.Dry Island has developed a micro cultivation facility on an 1/2-acre parcel of land, in Stettler, Alberta, that is half way between Calgary and Edmonton. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by Delta 9. Dry Island’s initial plan is to focus on growing two strains of 20+ THC before it expands its product offering. Dry Island owns two additional half acre adjacent lots to the property which are slated for future expansion. The well-rounded Dry Island team has a strong entrepreneurial background, with experience in construction and agriculture. The Dry Island team is committed and passionate about growing premium craft cannabis and looks forward to building a leading craft cannabis company in Alberta.
Is New 90 Day High Low • Jan 28New 90-day low: CA$0.49The company is down 14% from its price of CA$0.57 on 29 October 2020. The Canadian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 79% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$3.34 per share.
Recent Insider Transactions • Jan 22Independent Director recently sold CA$75k worth of stockOn the 13th of January, Hugh Aird sold around 150k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$679k more than they bought in the last 12 months.
Recent Insider Transactions • Jan 17Independent Director recently sold CA$75k worth of stockOn the 13th of January, Hugh Aird sold around 150k shares on-market at roughly CA$0.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$679k more than they bought in the last 12 months.
Recent Insider Transactions • Dec 25Co-Founder recently bought CA$98k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly CA$0.55 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by CA$303k.
공고 • Dec 24Delta 9 Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Manitoba based Micro Cultivation partner, Alicanto Gardens Ltd. (“Alicanto”). Alicanto is an arm’s length third party in which the company has no ownership control or interest. On December 18, 2020, Alicanto confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). As one of Delta 9’s Micro Cultivation partners, Alicanto entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the Alicanto brand and other services supporting the acquisition of the Health Canada license. The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are based on retrofitted 40-foot shipping containers. Alicanto’s production facility has been designed and built using this turnkey and state of the art Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Alicanto for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Delta 9 has now successfully licensed over 100 Grow Pods in third party facilities across Canada. Alicanto has developed a state-of-the-art micro cultivation facility on an 80-acre parcel of land, about ten minutes from Morris and an hour south of Winnipeg. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by Delta 9. Alicanto’s initial plan is to focus on growing a single strain of high THC before it expands its product offering. The well-rounded Alicanto team has a strong entrepreneurial background, with extensive experience in building a $50 million distribution business from the ground up over the last decade. The Alicanto team is committed and passionate about growing premium craft cannabis and looks forward to building a leading craft cannabis company in Manitoba.
분석 기사 • Dec 24John Arbuthnot Is The Co-Founder of Delta 9 Cannabis Inc. (TSE:DN) And They Just Picked Up 1.0% More SharesWhilst it may not be a huge deal, we thought it was good to see that the Delta 9 Cannabis Inc. ( TSE:DN ) Co-Founder...
Is New 90 Day High Low • Dec 24New 90-day low: CA$0.52The company is down 7.0% from its price of CA$0.56 on 24 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 67% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$3.51 per share.
공고 • Dec 23Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 5.000001 million.Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 5.000001 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,090,910 Price\Range: CAD 0.55 Discount Per Security: CAD 0.0385
공고 • Dec 16Delta 9 Partners with Emterra Environmental to Create Sustainable Recycling and Landfill Diversion Program for Canadian Cannabis IndustryDELTA 9 CANNABIS INC. has partnered with Emterra Environmental, and a number of leading Canadian cannabis producers, to create a sustainable recycling program for cannabis packaging and disposable vape pens and a landfill diversion program for vape cartridges, that will help the Canadian cannabis industry transition to a circular economy. The new program will have two components. The first provides customers with a convenient option for the recycling of cannabis packaging similar to the well-known Blue Box Program. The second focuses on landfill diversion and uses the best technology currently available for the recycling of disposable vape cartridges and vape pens. The program will accept cannabis packaging, disposable vape pens and vape cartridges from every Licensed Producer, regardless of brand.
공고 • Dec 12Delta 9 Cannabis Inc. Completes Final Services Milestone Under an Agreement with Prairie Craft CanopyDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Prairie Craft Canopy. PCC is an arm's length third party in which the Company has no ownership control or interest. As one of Delta 9's Micro Cultivation partners, PCC entered into a Strategic Cooperation Agreement ("SCA") with the company whereby Delta 9 provides services relating to the cannabis production, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the PCC brand and other services supporting the acquisition of the Health Canada license. On December 4, 2020, PCC confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the "Health Canada License"). PCC has developed a micro cultivation facility on a 10-acre parcel of land. The facility is in the RM of Edenwold No.158 just minutes from Regina, Saskatchewan. This new facility houses a micro cultivation license, including twelve new grow pod systems, and a proprietary craft growing approach developed by PCC. The facility includes some of the latest technology surrounding climate control and grow room automation. PCC plans to incorporate more innovative sustainability in future phases of expansion. PCC expects this facility to be the first step in a more significant growth strategy, as it makes plans for a second micro cultivation license and that will include another twelve-grow pod production capability in the near term. The well-rounded PCC Team has a strong entrepreneurial background, with an executive team that has many years experience in growing start-up companies. The PCC Team is committed and passionate about growing premium craft cannabis and looks forward to building a craft cannabis company in Saskatchewan. PCC expects to be in production by January, 2021 with plans to grow a unique strain of premium craft cannabis that consumers are looking for.
공고 • Nov 26Delta 9 Cannabis Inc. Develops Proprietary Decontamination Technology to Help Fight COVID-19 PandemicDelta 9 Cannabis Inc. announced that it has developed and validated new proprietary decontamination equipment, branded the “Decontamination Pod” (or “D-Pod”), which can be used to decontaminate medical supplies, personal protective equipment (“PPE”), and other equipment. Canadian and US patent applications have been filed on behalf of the Company for the D-Pod, which is a standard shipping container retrofitted to include heating and ultraviolet light technologies. When PPE or other materials are placed inside the treatment area of the D-Pod, the combination of heat and UVC is sufficient to kill the COVID-19 virus. The Company, through a newly incorporated and partially owned subsidiary, Blue Horseshoe Manufacturing Inc., plans to manufacture and distribute the new technology across North America, providing a new tool for governments, health care facilities, long-term care facilities, businesses, and First Nations in their fight against COVID-19. The Company will leverage the success of its cannabis grow pod division which has produced and installed over 500 pods for in-house and third-party facilities since 2017 and use its existing cannabis grow pod manufacturing facilities in Winnipeg to manufacture the first D-Pods. Management believes that the Company will quickly be able to ramp up production capacity to 16 to 20 D-Pods per month, while working with other Canadian manufacturers to compliment its internal capacity. The D-Pods are expected to sell for approximately $250,000 per unit. The Company has already received inquiries from groups interested in deploying the technology and expects to begin taking orders in the coming week. The technology used in the D-Pods was originally developed in partnership between Delta 9, RSR Project Management Ltd., Northern Green Homes Inc., and Connco Electric and the finished D-Pod was tested and validated by an independent and accredited third party lab, BioScision Pharma Inc., which confirmed that the technology should be effective in decontaminating materials which may be contaminated with the COVID-19 virus. The D-Pod is the first innovation of Delta 9’s grow pod business unit which can be used as a tool in the fight against COVID-19. The Company is now developing additional technologies which can decontaminate equipment at low temperatures and modular storage and transport units which can be used to store and distribute vaccines while maintaining quality and stability.
공고 • Nov 25Delta 9 Launches Click & Collect and Same Day Delivery Service in Thompson & Brandon, ManitobaDELTA 9 CANNABIS INC. announced that it has expanded its click-and-collect and same-day home delivery service program to the Thompson and Brandon, Manitoba markets. As a result, Delta 9 becomes the only retail store chain offering the above services in Winnipeg, Brandon, and Thompson, Manitoba. The Company is pleased to provide the next phase of convenience for customers and further enhance safety during the COVID-19 pandemic by minimizing contact time between customers and staff. With the click of a mouse, customers can browse and sort through a complete inventory of cannabis products by store and reserve any products from whichever retail location that is most convenient. Delta 9’s online platform features allow an order to be ready in two hours or less along with delivery services for all Manitobans. Customers will receive direct email and text order updates from their chosen store and can visit the Delta 9 website to seamlessly place an order. Customer service operators are available by phone or online chat.
공고 • Nov 20Delta 9 Cannabis Inc. Completes Final Services Milestone Under an Agreement with Ahahswinis Green Investments LtdDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Ahahswinis Green Investments Ltd. ('Ahahswinis') which is 100% owned by Hupacasath First Nation. Ahahswinis is an arms length third party in which Delta 9 has no ownership control or interest. As one of Delta 9’s micro cultivation partners, Ahahswinis entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On November 13, 2020, Ahahswinis confirmed it has reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Ahahswinis’s facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Ahahswinis for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. The Hupacasath First Nation has owned and occupied their traditional territory in Central Vancouver Island for thousands of years. Their goal is to enhance the quality of life for their people by providing jobs and economic development opportunities so families can support themselves. They have invested $1.9 million in the 4,560 square foot micro cultivation operation with 12 Delta 9 Grow Pods, located outside of Port Alberni Vancouver Island, British Columbia.
Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
공고 • Oct 30Delta 9 Cannabis Inc. to Report Q3, 2020 Results on Nov 12, 2020Delta 9 Cannabis Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 12, 2020
공고 • Oct 27Delta 9 Cannabis Inc. Enters into Strategic Cooperation Agreement with Paradise Cannabis LtdDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, Paradise Cannabis LTD. Paradise is an arm’s length third party in which the Company has no ownership control or interest. As one of Delta 9’s Micro Cultivation partners, Paradise entered into a Strategic Cooperation Agreement with the company whereby Delta 9 provides services relating to the cannabis production facility design, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing and other services supporting the acquisition of the Health Canada license.